GoAI
Get started
Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd.

SLGL

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$77.73

−$0.765 · -0.97%

Aug 21, 4:00 PM ET

SLGL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

36

Expensive

Momentum

77

Gaining

Sentiment

45

Mixed

Risk resilience

46

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IL
CEO
Moshe Arkin
Listed since
Feb 1, 2018
Employees
28

Market position

Day range

Current $77.73

52-week range

Current $77.73

Open
$81.92
Previous close
$78.495
Volume
33.32K
0.83× average
Average volume
39.94K
Average daily volume
Market cap
254.1M USD
Beta
1.16
Market reference 1
50-day average
$78.4764
-0.95% below average
200-day average
$67.3972
+15.33% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
107.35M USD
P/E (TTM)
-13.78×
P/B (TTM)
5.29×
P/S (TTM)
141.56×
EV / EBITDA
-14.45×
Earnings yield
-5.22%
Free cash flow yield
0.23%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
67.08%
Operating margin
-986.96%
Net margin
-910.14%
Return on equity
-26.86%
Return on assets
-20.48%
Return on invested capital
-31.10%

Financial health

Debt / equity
0.02×
Current ratio
4.37×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends299%-496%-1290%-2084%Gross margin, FY2021: 34.83%Gross margin, FY2022: -226.60%Gross margin, FY2023: -1414.86%Gross margin, FY2024: 97.98%Gross margin, FY2025: 100.00%Operating margin, FY2021: 9.48%Operating margin, FY2022: -418.34%Operating margin, FY2023: -1885.78%Operating margin, FY2024: -104.13%Operating margin, FY2025: -38.88%Net margin, FY2021: 10.30%Net margin, FY2022: -384.32%Net margin, FY2023: -1752.77%Net margin, FY2024: -91.70%Net margin, FY2025: -31.60%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 34.83%. Gross margin FY2022 -226.60%. Gross margin FY2023 -1414.86%. Gross margin FY2024 97.98%. Gross margin FY2025 100.00%. Operating margin FY2021 9.48%. Operating margin FY2022 -418.34%. Operating margin FY2023 -1885.78%. Operating margin FY2024 -104.13%. Operating margin FY2025 -38.88%. Net margin FY2021 10.30%. Net margin FY2022 -384.32%. Net margin FY2023 -1752.77%. Net margin FY2024 -91.70%. Net margin FY2025 -31.60%.

Income trends

Revenue

19.39M USD+68.04%

Operating income

−7.54M USD+37.26%

Net income

−6.13M USD+42.09%
Income trends across reported periods37.33M USD13.1M USD−11.13M USD−35.36M USDRevenue, FY2021: 31.27M USDRevenue, FY2022: 3.88M USDRevenue, FY2023: 1.55M USDRevenue, FY2024: 11.54M USDRevenue, FY2025: 19.39M USDOperating income, FY2021: 2.96M USDOperating income, FY2022: −16.24M USDOperating income, FY2023: −29.31M USDOperating income, FY2024: −12.01M USDOperating income, FY2025: −7.54M USDNet income, FY2021: 3.22M USDNet income, FY2022: −14.92M USDNet income, FY2023: −27.24M USDNet income, FY2024: −10.58M USDNet income, FY2025: −6.13M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 31.27M USD. Revenue FY2022 3.88M USD. Revenue FY2023 1.55M USD. Revenue FY2024 11.54M USD. Revenue FY2025 19.39M USD. Operating income FY2021 2.96M USD. Operating income FY2022 −16.24M USD. Operating income FY2023 −29.31M USD. Operating income FY2024 −12.01M USD. Operating income FY2025 −7.54M USD. Net income FY2021 3.22M USD. Net income FY2022 −14.92M USD. Net income FY2023 −27.24M USD. Net income FY2024 −10.58M USD. Net income FY2025 −6.13M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue19.39M USD11.54M USD1.55M USD3.88M USD31.27M USD
Cost of goods sold—233K USD342K USD12.68M USD20.38M USD
Gross profit19.39M USD11.31M USD−21.99M USD−8.8M USD10.89M USD
Research and development22.8M USD17.8M USD23.54M USD12.68M USD20.38M USD
Selling, general, and administrative4.18M USD5.75M USD7.37M USD7.45M USD8.45M USD
Operating expenses26.93M USD23.32M USD7.32M USD7.45M USD7.93M USD
Interest income1.41M USD1.43M USD2.07M USD1.32M USD257K USD
Depreciation and amortization109K USD233K USD342K USD562K USD880K USD
Operating income−7.54M USD−12.01M USD−29.31M USD−16.24M USD2.96M USD
Net income−6.13M USD−10.58M USD−27.24M USD−14.92M USD3.22M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$110

41.52% upside
Past 12 months12-month forecastHigh $110Average $110Low $110

SLGL news

globenewswire.com

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

NESS ZIONA, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial…

Read source
zacks.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.84.

Read source
globenewswire.com

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten offering, raising…

Read source

SLGL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SLGL

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Israel Innovative Technology ETF logoARK Israel Innovative Technology ETFIZRL
Market value
2.2M
Weight
1.65%
AUM
136.9M USD
Expense ratio
0.49%
Price / 1D
$29.04+0.87%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
118.92K
Weight
0.52%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%

Continue in GoAI

Research SLGL

research.disclaimer